Trials / Completed
CompletedNCT04130061
Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
Safety and Feasibility Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation After Coronary Artery Bypass Grafting
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human Amniotic Membrane | Epicardial application of human amniotic membrane during cardiac surgery |
Timeline
- Start date
- 2019-10-11
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2019-10-17
- Last updated
- 2026-04-09
- Results posted
- 2024-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04130061. Inclusion in this directory is not an endorsement.